Therapeutic potential of vitamin B₁ derivative benfotiamine from diabetes to COVID-19

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Whitfield KC, Smith TJ, Rohner F, Wieringa FT, Green TJ. Thiamine fortification strategies in low- and middle-income settings: a review. Ann. NY Acad. Sci. 1498(1), 29–45 (2021).
  MedlineGoogle Scholar
• 2. Beltramo E, Mazzeo A, Porta M. Thiamine and diabetes: back to the future? Acta Diabetol. 58(11), 1433–1439 (2021).
  Medline CASGoogle Scholar
• 3. Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry 53(5), 821–835 (2014).
  Medline CASGoogle Scholar
• 4. Zhao N, Zhong C, Wang Y et al. Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol. Dis. 29(2), 176–185 (2008).
  MedlineGoogle Scholar
• 5. Langlais PJ, Zhang SX, Savage LM. Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models. Metab. Brain Dis. 11(1), 19–37 (1996).
  Medline CASGoogle Scholar
• 6. Polegato BF, Pereira AG, Azevedo PS et al. Role of thiamin in health and disease. Nutr. Clin. Pract. 34(4), 558–564 (2019).
  MedlineGoogle Scholar
• 7. Lonsdale D. Thiamin. Adv. Food Nutr. Res. 83, 1–56 (2018).
  MedlineGoogle Scholar
• 8. DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, Ventura HO. Thiamine supplementation for the treatment of heart failure: a review of the literature. Congest. Heart Fail. 19(4), 214–222 (2013).
  Medline CASGoogle Scholar
• 9. Cook CC. Prevention and treatment of Wernicke–Korsakoff syndrome. Alcohol Alcohol. 35(1), 19–20 (2000).
  CASGoogle Scholar
• 10. Prakasha SR, Mustafa AS, Baikunje S, Subramanyam K. “Dry” and “wet” beriberi mimicking critical illness polyneuropathy. Ann. Indian Acad. Neurol. 16(4), 687–689 (2013).
  MedlineGoogle Scholar
• 11. Bettendorff L. Update on thiamine triphosphorylated derivatives and metabolizing enzymatic complexes. Biomolecules 11(11), 1645 (2021).
  Medline CASGoogle Scholar
• 12. Bettendorff L. Thiamine. In: Basic Nutrition and Metabolism; Present Knowledge in Nutrition (11th Edition). Marriott BBirt DStalling VYates A (Eds). Academic Press, MA, USA, 676 (2020).
  Google Scholar
• 13. Bettendorff L, Wins P. Thiamine derivatives in excitable tissues: metabolism, deficiency and neurodegenerative diseases. Recent Res. Devel. Neurochem. (2), 37–62 (1999). • This is an excellent article that describes the role of various thiamine derivatives in neurological complications.
  Google Scholar
• 14. Gangolf M, Czerniecki J, Radermecker M et al. Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PloS One 5(10), e13616 (2010).
  MedlineGoogle Scholar
• 15. Sambon M, Gorlova A, Demelenne A et al. Dibenzoylthiamine has powerful antioxidant and anti-inflammatory properties in cultured cells and in mouse models of stress and neurodegeneration. Biomedicines 8(9), 361 (2020).
  CASGoogle Scholar
• 16. Tylicki A, Łotowski Z, Siemieniuk M, Ratkiewicz A. Thiamine and selected thiamine antivitamins – biological activity and methods of synthesis. Biosci. Rep. 38(1), BSR20171148 (2018).
  Medline CASGoogle Scholar
• 17. Bitsch R, Wolf M, Möller J, Heuzeroth L, Grüneklee D. Bioavailability assessment of the lipophilic benfotiamine as compared to water-soluble thiamin derivative. Ann. Nutri. Metab. 35(5), 292–296 (1991).
  Medline CASGoogle Scholar
• 18. Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid. Based Complement. Alternat. Med. 3, 49–59 (2006). • This is an important review article to learn in detail about thiamine and its derivatives.
  MedlineGoogle Scholar
• 19. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int. J. Clin. Pharmacol. Ther. 36, 216–221 (1998).
  Medline CASGoogle Scholar
• 20. Abudukelimu A, Barberis M, Redegeld FA, Sahin N, Westerhoff HV. Predictable irreversible switching between acute and chronic inflammation. Front. Immunol. 9, 1596 (2018).
  MedlineGoogle Scholar
• 21. Biswas SK. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid. Med. Cell Longev. 5698931 doi.org/10.1155/2016/5698931 (2016).
  MedlineGoogle Scholar
• 22. de Andrade JAA, Gayer CRM, Nogueira NPA et al. The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. J. Inflamm. (Lond.) 11, 11 (2014).
  MedlineGoogle Scholar
• 23. Donnino MW, Andersen LW, Chase M et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study. Crit. Care Med. 44(2), 360–367 (2016).
  Medline CASGoogle Scholar
• 24. Miyamoto Y, Aso S, Iwagami M et al. Association between IV thiamine and mortality in patients with septic shock: a nationwide observational study. Crit. Care Med. 48(8), 1135–1139 (2020).
  Medline CASGoogle Scholar
• 25. Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest. Ophthalmol. Vis. Sci. 50(5), 2276–2282 (2009).
  MedlineGoogle Scholar
• 26. Bozic I, Savic D, Laketa D et al. Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia. PLoS One 10(2), e0118372 (2015).
  MedlineGoogle Scholar
• 27. Yadav UC, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic. Biol. Med. 48(10), 1423–1434 (2010).
  Medline CASGoogle Scholar
• 28. Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic. Biol. Med. 52(1), 182–190 (2012).
  Medline CASGoogle Scholar
• 29. Ahmed LA, Hassan OF, Galal O, Mansour DF, El-Khatib A. Beneficial effects of benfotiamine, a NADPH oxidase inhibitor, in isoproterenol-induced myocardial infarction in rats. PLoS One 15(5), e0232413 (2020).
  Medline CASGoogle Scholar
• 30. Thakur KT, Albanese E, Giannakopoulos P et al. Neurological disorders. In: Mental, Neurological, and Substance Use Disorders: Disease Control Priorities (3rd Edition, Volume 4). Patel VChisholm DDua TLaxminarayan RMedina-Mora ME (Eds). The World Bank, DC, USA (2016).
  Google Scholar
• 31. Sengoku R. Aging and Alzheimer's disease pathology. Neuropathology 40(1), 22–29 (2020).
  MedlineGoogle Scholar
• 32. Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell 18(6), e13031 (2019).
  Medline CASGoogle Scholar
• 33. Perez-Pineiro R, Bjorndahl TC, Berjanskii MV et al. The prion protein binds thiamine. FEBS J. 278(21), 4002–4014 (2011).
  Medline CASGoogle Scholar
• 34. Nakamura ZM, Tatreau JR, Rosenstein DL, Park EM. Clinical characteristics and outcomes associated with high-dose intravenous thiamine administration in patients with encephalopathy. Psychosomatics 59(4), 379–387 (2018).
  MedlineGoogle Scholar
• 35. Isen DR, Kline LB. Neuro-ophthalmic manifestations of Wernicke encephalopathy. Eye Brain 12, 49–60 (2020).
  MedlineGoogle Scholar
• 36. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern. Med. J. 44(9), 911–915 (2014).
  Medline CASGoogle Scholar
• 37. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. Int. J. Mol. Sci. 22(11), 5418 (2021).
  Medline CASGoogle Scholar
• 38. Manzardo AM, He J, Poje A, Penick EC, Campbell J, Butler MG. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend. 133(2), 562–570 (2013).
  Medline CASGoogle Scholar
• 39. Ikeda K, Liu X, Kidac K et al. Thiamine as a neuroprotective agent after cardiac arrest. Resuscitation 105, 138–144 (2016).
  MedlineGoogle Scholar
• 40. Gibson GE, Hirsch JA, Fonzetti P, Jordan BD, Cirio RT, Elder J. Vitamin B1 (thiamine) and dementia. Ann. NY Acad. Sci. 1367(1), 21–30 (2016).
  Medline CASGoogle Scholar
• 41. Toledo Nunes P, Vedder LC, Deak T, Savage LM. A pivotal role for thiamine deficiency in the expression of neuroinflammation markers in models of alcohol-related brain damage. Alcohol. Clin. Exp. Res. 43(3), 425–438 (2019).
  MedlineGoogle Scholar
• 42. Smith TJ, Johnson CR, Koshy R et al. Thiamine deficiency disorders: a clinical perspective. Ann. NY Acad. Sci. 1498(1), 9–28 (2021).
  MedlineGoogle Scholar
• 43. Chou WP, Chang YH, Lin HC, Chang YH, Chen YY, Ko CH. Thiamine for preventing dementia development among patients with alcohol use disorder: a nationwide population-based cohort study. Clin. Nutr. 38(3), 1269–1273 (2019).
  Google Scholar
• 44. Sheu KF, Clarke DD, Kim YT, Blass JP, Harding BJ, DeCicco J. Studies of transketolase abnormality in Alzheimer's disease. Arch. Neurol. 45, 841–845 (1988).
  Medline CASGoogle Scholar
• 45. Pan X, Chen Z, Fei G et al. Long-term improvement after benfotiamine administration in patients with Alzheimer's disease. Neurosci. Bull. 32(6), 591–596 (2016).
  Medline CASGoogle Scholar
• 46. Tapias V, Jainuddin S, Ahuja M et al. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum. Mol. Genet. 27(16), 2874–2892 (2018).
  Medline CASGoogle Scholar
• 47. Vignisse J, Sambon M, Gorlova A et al. Thiamine and benfotiamine prevent stress-induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels. Mol. Cell. Neurosci. 82, 126–136 (2017).
  Medline CASGoogle Scholar
• 48. Sambon M, Napp A, Demelenne A et al. Thiamine and benfotiamine protect neuroblastoma cells against paraquat and β-amyloid toxicity by a coenzyme-independent mechanism. Heliyon 5(5), e01710 (2019).
  MedlineGoogle Scholar
• 49. Markova N, Bazhenova N, Anthony DC et al. Thiamine and benfotiamine improve cognition and ameliorate GSK-3β-associated stress-induced behaviours in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 75, 148–156 (2017).
  Medline CASGoogle Scholar
• 50. Gorlova A, Pavlov D, Anthony DC et al. Thiamine and benfotiamine counteract ultrasound-induced aggression, normalize AMPA receptor expression and plasticity markers, and reduce oxidative stress in mice. Neuropharmacology 156, 107543 (2019).
  Medline CASGoogle Scholar
• 51. Gibson GE, Luchsinger JA, Cirio R et al. Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase IIa clinical trial. J. Alzheimers Dis. 78(3), 989–1010 (2020).
  Medline CASGoogle Scholar
• 52. Sang S, Pan X, Chen Z et al. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not. Alzheimers Res Ther. 10(1), 26 (2018).
  MedlineGoogle Scholar
• 53. Pacal L, Kuricova K, Kankova K. Evidence for altered thiamine metabolism in diabetes: is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J. Diabetes 5(3), 288–295 (2014).
  MedlineGoogle Scholar
• 54. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol. Rev. 93(1), 137–188 (2013).
  Medline CASGoogle Scholar
• 55. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26(3), 380–392 (2005). •• This is an important review article that describes how the polyol pathway mediates secondary diabetic complications.
  Medline CASGoogle Scholar
• 56. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11(4), 294–329 (2006).
  MedlineGoogle Scholar
• 57. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. Int. Sch. Res. Notices 2013, 343560 (2013).
  Google Scholar
• 58. Song J, Yang X, Yan LJ. Role of pseudohypoxia in the pathogenesis of Type 2 diabetes. Hypoxia (Auckl.) 7, 33–40 (2019).
  MedlineGoogle Scholar
• 59. Aragno M, Mastrocola R. Dietary sugars and endogenous formation of advanced glycation endproducts: emerging mechanisms of disease. Nutrients 9(4), 385 (2017).
  Google Scholar
• 60. Choei H, Sasaki N, Takeuchi M et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol. 108(3), 189–193 (2004).
  Medline CASGoogle Scholar
• 61. González I, Morales MA, Rojas A. Polyphenols and AGEs/RAGE axis. Trends and challenges. Food Res. Int. 129, 108843 (2020).
  MedlineGoogle Scholar
• 62. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 47(6), 859–866 (1998).
  Medline CASGoogle Scholar
• 63. Tabit CE, Shenouda SM, Holbrook M et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 127(1), 86–95 (2013).
  Medline CASGoogle Scholar
• 64. Elmouelhi N, Aich U, Paruchuri VD et al. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J. Med. Chem. 52(8), 2515–2530 (2009).
  Medline CASGoogle Scholar
• 65. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl Acad. Sci. USA 97, 12222–12226 (2000).
  Medline CASGoogle Scholar
• 66. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790 (2000). •• This is an important article that identifies three major pathways activated during hyperglycemia-induced secondary complications.
  Medline CASGoogle Scholar
• 67. Rosner EA, Strezlecki KD, Clark JA, Lieh-Lai M. Low thiamine levels in children with Type 1 diabetes and diabetic ketoacidosis: a pilot study. Pediatr. Crit. Care Med. 16(2), 114–118 (2015).
  MedlineGoogle Scholar
• 68. Anwar A, Azmi AM, Siddiqui J et al. Thiamine level in Type I and Type II diabetes mellitus patients: a comparative study focusing on hematological and biochemical evaluations. Cureus 12(5), e8027 (2020).
  MedlineGoogle Scholar
• 69. Hiffler L, Rakotoambinina B, Lafferty N, Garcia DM. Thiamine deficiency in tropical pediatrics: new insights into a neglected but metabolic challenge. Front. Nutr. 3, 16 (2016).
  MedlineGoogle Scholar
• 70. Beltramo E, Berrone E, Tarallo S et al. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol. 45, 131 (2008).
  Medline CASGoogle Scholar
• 71. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9(3), 294–299 (2003). •• This is a landmark paper on benfotiamine where the results indicate that benfotiamine prevents major pathways responsible for diabetic complications.
  Medline CASGoogle Scholar
• 72. Feldman EL, Callaghan BC, Pop-Busui R et al. Diabetic neuropathy. Nat. Rev. Dis. Primers 5, 41 (2019).
  MedlineGoogle Scholar
• 73. Yang H, Sloan G, Ye Y et al. New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection and precision medicine. Front. Endocrinol. 10, 3389 (2020).
  Google Scholar
• 74. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr. Neurol. Neurosci. Rep. 14, 473 (2014).
  MedlineGoogle Scholar
• 75. Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol. Res. 80, 21–35 (2014).
  Medline CASGoogle Scholar
• 76. Vafadar GL, Behnam RM, Matin MM, Mahdavi-Shahri N. Benfotiamine reduced collagen IV contents of sciatic nerve in hyperglycemic rats. J. Diabetes Metab. Disord. 20(1), 21–30 (2021).
  MedlineGoogle Scholar
• 77. Gadau S, Emanueli C, Van Linthout S et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49(2), 405–420 (2006).
  Medline CASGoogle Scholar
• 78. Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur. J. Pharmacol. 530(1–2), 48–53 (2006).
  Medline CASGoogle Scholar
• 79. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci. Lett. 394(2), 158–162 (2006).
  Medline CASGoogle Scholar
• 80. Stracke H, Hammes HP, Werkmann D et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 109(6), 330–336 (2001).
  Medline CASGoogle Scholar
• 81. Karaganis S, Song XJ. B vitamins as a treatment for diabetic pain and neuropathy. J. Clin. Pharm. Ther. 46(5), 1199–1212 (2021).
  Medline CASGoogle Scholar
• 82. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy – a three-week randomized, controlled pilot study (BEDIP study). Int. J. Clin. Pharmacol. Ther. 43(2), 71–77 (2005).
  Medline CASGoogle Scholar
• 83. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp. Clin. Endocrinol. Diabetes 116(10), 600–605 (2008).
  Medline CASGoogle Scholar
• 84. Fraser DA, Diep LM, Hovden IA et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with Type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35(5), 1095–1097 (2012).
  Medline CASGoogle Scholar
• 85. Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 139, 7–14 (2017).
  MedlineGoogle Scholar
• 86. Beltramo E, Nizheradze K, Berrone E, Tarallo S, Porta M. Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes. Diabetes Metab. Res. Rev. 25(7), 647–656 (2009).
  Medline CASGoogle Scholar
• 87. Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J. Diabetes Res. 2017, 8637138 (2017).
  MedlineGoogle Scholar
• 88. Sawaf H, Thomas G, Taliercio JJ, Nakhoul G, Vachharajani TJ, Mehdi A. Therapeutic advances in diabetic nephropathy. J. Clin. Med. 11(2), 378 (2022).
  Medline CASGoogle Scholar
• 89. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52(8), 2110–2120 (2003).
  Medline CASGoogle Scholar
• 90. Müller-Krebs S, Nissle K, Tsobaneli J et al. Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid. Front. Med. (Lausanne) 2, 10 (2015).
  MedlineGoogle Scholar
• 91. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 53(7), 1506–1516 (2010).
  Medline CASGoogle Scholar
• 92. Alkhalaf A, Klooster A, van Oeveren W et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33(7), 1598–1601 (2010).
  Medline CASGoogle Scholar
• 93. Alkhalaf A, Kleefstra N, Groenier KH et al. Effect of benfotiamine on advanced glycation end products and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 7(7), e40427 (2012).
  Medline CASGoogle Scholar
• 94. Ustuner MA, Kaman D, Colakoglu N. Effects of benfotiamine and coenzyme Q10 on kidney damage induced gentamicin. Tissue Cell 49(6), 691–696 (2017).
  Medline CASGoogle Scholar
• 95. Kihm LP, Müller-Krebs S, Klein J et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J. Am. Soc. Nephrol. 22(5), 914–926 (2011).
  Medline CASGoogle Scholar
• 96. Jovic TH, Ali SR, Ibrahim N et al. Could vitamins help in the fight against COVID-19? Nutrients 12(9), 2550 (2020).
  CASGoogle Scholar
• 97. Akashi Y, Suzuki H, Kanemoto K et al. Thiamine concentrations in newly hospitalized elderly patients with infectious diseases at a community hospital in Japan. J. Nutr. Sci. Vitaminol. (Tokyo) 64(3), 209–214 (2018).
  Medline CASGoogle Scholar
• 98. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int. J. STD AIDS 12(6), 407–409 (2001).
  Medline CASGoogle Scholar
• 99. Shoji S, Furuishi K, Ogata A et al. An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B. Biochem. Biophys. Res. Commun. 249(3), 745–753 (1998).
  Medline CASGoogle Scholar
• 100. L Ng Kv, Nguyễn LT. The role of thiamine in HIV infection. Int. J. Infect. Dis. 17(4), e221–e227 (2013). • This study describes how vitamin B1 could be involved in infectious diseases.
  MedlineGoogle Scholar
• 101. Tanaka T, Sohmiya K, Kono T et al. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol. Cell. Biochem. 299(1–2), 23–35 (2007).
  Medline CASGoogle Scholar
• 102. Sriram K, Manzanares W, Joseph K. Thiamine in nutrition therapy. Nutr. Clin. Pract. 27(1), 41–50 (2012).
  MedlineGoogle Scholar
• 103. Al Sulaiman K, Aljuhani O, Al Dossari M et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit. Care 25(1), 223 (2021).
  MedlineGoogle Scholar
• 104. Branco de Oliveira MV, Irikura S, Lourenço FHB et al. Encephalopathy responsive to thiamine in severe COVID-19 patients. Brain Behav. Immun. Health 14, 100252 (2021).
  MedlineGoogle Scholar
• 105. Vatsalya V, Li F, Frimodig JC, Gala KS et al. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: thiamine efficacy and safety, in-vitro evidence and pharmacokinetic profile. Front. Pharmacol. 11, 598128 (2021).
  MedlineGoogle Scholar
• 106. Kousar S, Sheikh MA, Asghar M. Antiglycation activity of thiamin-HCl and benfotiamine in diabetic condition. J. Pak. Med. Assoc. 62(10), 1033–1038 (2012).
  MedlineGoogle Scholar
• 107. Bondar A, Popa AR, Papanas N et al. Diabetic neuropathy: a narrative review of risk factors, classification, screening and current pathogenic treatment options (review). Exp. Ther. Med. 22(1), 690 (2021).
  Medline CASGoogle Scholar
• 108. Sheng L, Cao W, Lin P et al. Safety, tolerability and pharmacokinetics of single and multiple ascending doses of benfotiamine in healthy subjects. Drug Des. Devel. Ther. 15, 1101–1110 doi.org/10.2147/DDDT.S296197 (2021). •• An important clinical study that demonstrates benfotiamine safety and tolerability in healthy humans.
  MedlineGoogle Scholar
• 109. Volvert ML, Seyen S, Piette M et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 8 doi.org/10.1186/1471-2210-8-10, 10 (2008).
  MedlineGoogle Scholar
• 110. Biró A, Markovics A, Fazekas MÉ et al. Allithiamine alleviates hyperglycaemia-induced endothelial dysfunction. Nutrients 12(6), 1690 (2020).
  CASGoogle Scholar
• 111. Choi EJ, Jeon CH, Park DH, Kwon TH. Allithiamine exerts therapeutic effects on sepsis by modulating metabolic flux during dendritic cell activation. Mol. Cells 43(11), 964–973 (2020).
  Medline CASGoogle Scholar
• 112. Van Reeth O. Pharmacologic and therapeutic features of sulbutiamine. Drugs Today 35, 187–192 (1999).
  Medline CASGoogle Scholar
• 113. Loo H, Poirier MF, Ollat H et al. Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes. Encephale 26(2), 70–75 (2000).
  Medline CASGoogle Scholar
• 114. Shinozaki H. Cardiac action of thiamine derivatives in guinea pig atria. J. Nutr. Sci. Vitaminol. 22, 29–34 (1976).
  Medline CASGoogle Scholar
• 115. Do JY, Kim J, Kim MJ et al. Fursultiamine alleviates choroidal neovascularization by suppressing inflammation and metabolic reprogramming. Invest. Ophthalmol. Vis. Sci. 61(12), 24 (2020).
  Medline CASGoogle Scholar
• 116. Bönhof GJ, Sipola G, Strom A et al. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with Type 2 diabetes with symptomatic polyneuropathy. BMJ Open 12(2), e057142 (2022).
  MedlineGoogle Scholar
• 117. Wilson RB. Pathophysiology, prevention, and treatment of beriberi after gastric surgery. Nutr. Rev. 78(12), 1015–1029 (2020).
  MedlineGoogle Scholar
• 118. Manzardo AM, Pendleton T, Poje A, Penick EC, Butler MG. Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity. Drug Alcohol Depend. 152, 257–263 (2015).
  Medline CASGoogle Scholar
• 119. Jonus HC, Byrnes CC, Kim J et al. Thiamine mimetics sulbutiamine and benfotiamine as a nutraceutical approach to anticancer therapy. Biomed. Pharmacother. 121, 109648 (2020).
  Medline CASGoogle Scholar
• 120. Iimura Y, Andoh S, Kawamata T et al. Thiamine deficiency and neurological symptoms in patients with hematological cancer receiving chemotherapy: a retrospective analysis. J. Neurosci. Rural Pract. 12(4), 726–732 (2021).
  MedlineGoogle Scholar
• 121. Iimura Y, Kurokawa T, Andoh S et al. Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy. Biomed. Pharmacother. 141, 111929 (2021).
  Medline CASGoogle Scholar
• 122. Peterson CT, Rodionov DA, Osterman AL, Peterson SN. B vitamins and their role in immune regulation and cancer. Nutrients 12(11), 3380 (2020).
  CASGoogle Scholar
• 123. Sabui S, Romero JM, Said HM. Developmental maturation of the colonic uptake process of the microbiota-generated thiamin pyrophosphate. Am. J. Physiol. Gastrointest. Liver Physiol. 320(5), G829–G835 (2021).
  Medline CASGoogle Scholar
• 124. Hung WW, Peng P, Tsai YC et al. Gut microbiota compositions and metabolic functions in Type 2 diabetes differ with glycemic durability to metformin monotherapy. Diabetes Res. Clin. Pract. (174), 108731 doi:10.1016/j.diabres.2021.108731 (2021).
  MedlineGoogle Scholar
• 125. Park SY, Faraci G, Nanda S et al. Gut microbiome in people living with HIV is associated with impaired thiamine and folate syntheses. Microb. Pathog. 160, 105209 (2021).
  Medline CASGoogle Scholar
• 126. Shakoor H, Feehan J, Mikkelsen K et al. Be well: a potential role for vitamin B in COVID-19. Maturitas 144, 108–111 (2021). • This article nicely describes the significance of B-vitamins in reducing the symptoms associated with COVID-19.
  Medline CASGoogle Scholar
• 127. Ranjbar M, Karbalaie Niya MH, Roham M et al. Serum level of vitamin D is associated with COVID-19 mortality rate in hospitalized patients. J. Res. Med. Sci. 26, 112 (2021).
  Medline CASGoogle Scholar
• 128. Jaun F, Boesing M, Lüthi-Corridori G et al. High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study-vitcov trial. Trials 23(1), 114 (2022).
  Medline CASGoogle Scholar